Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
在一项针对携带 KRAS G12C 突变的晚期实体瘤患者的 II 期临床试验中，KRAS G12C 抑制剂 Garsorasib 联合或不联合 EGFR 抗体西妥昔单抗，用于治疗结直肠癌患者。
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02274-z
Ruan, Dan-Yun; Wu, Hao-Xiang; Xu, Ye; Munster, Pamela N; Deng, Yanhong; Richardson, Gary; Yan, Dong; Lee, Myung-Ah; Lee, Keun-Wook; Pan, Hongming; Hager, Steven; Li, Xingya; Wei, Shaozhong; Hou, Xinfang; Underhill, Craig; Millward, Michael; Nordman, Ina; Zhang, Jingdong; Shan, Jianzhen; Han, Guohong; Grewal, Jaspreet; Gadgeel, Shirish M; Sanborn, Rachel E; Huh, Seok Jae; Hu, Xiaohua; Zhang, Yihong; Xiang, Ziyong; Luo, Laisheng; Xie, Xiaoxi; Shi, Zhe; Wang, Yaolin; Zhang, Ling; Wang, Feng; Xu, Rui-Hua
